Melanotan and Melanotan II: what they are, why they tan you, and the real risks

The system's oldest trick, taken without its safeguards — the MC1R pigment switch, flipped by a peptide the law never cleared.

Search for a way to tan without the sun and you will quickly meet "melanotan" — peptides sold online as injections or nasal sprays that genuinely darken skin. They are real pharmacology, not a gimmick: synthetic relatives of the body's own pigment hormone, α-MSH, built in a university lab to be far stronger and longer-lasting than the natural signal.^[1] But the most popular one is also unapproved everywhere, sold illegally, and tied to documented harms. This page explains what these compounds are, where they came from, and why they do what they do — it is education, not endorsement, and not medical advice.

Two melanotans — and the medicines they became

The confusing part is that "melanotan" names a small family, and most of it grew up to be legitimate. All of it traces to work at the University of Arizona in the 1980s to make stable, potent analogues of α-MSH — first as a possible tanning drug, then well beyond it.^[1][2]

• Melanotan-I — the linear analogue (chemists know it as NDP-α-MSH) developed for pigment. It became an approved drug: afamelanotide (Scenesse), a controlled-release implant for a rare light-sensitivity disorder. See the afamelanotide explainer.
• Melanotan II (MT-II) — a more potent cyclicredesign that hits MC1R, MC3R, MC4R and MC5R. It was the one pushed as a tanning agent, and it is the one that never became a medicine. This is the "melanotan" sold on the grey market.^[1][3]
• Its offspring — bremelanotide (Vyleesi), carved out of the MT-II scaffold, became an approved treatment for low sexual desire. See the full bremelanotide / PT-141 explainer.

So two of the three melanotan-lineage molecules cleared trials and reached pharmacies under controlled doses and forms. The middle one — MT-II — stayed in vials marked "research chemical, not for human use," which is how it dodges the rules it can't pass.^[22]

Born in a lab in Arizona

Native α-MSH is a poor drug: the body degrades it within minutes. The Arizona chemists fixed that by rebuilding it. Swapping in unnatural amino acids and, for MT-II, closing the peptide into a ring (a lactam bridge) locked the molecule into its active shape and shielded it from the enzymes that chew up the natural hormone. The result was a compound roughly a hundred times more potent than α-MSH and far longer-acting — small changes, an outsized effect.^[1] That is the quiet elegance of it: the tan is not a foreign trick imposed on the skin, but the body's own pigment signal, copied and made to last.

When MT-II first reached human volunteers, in a small phase-I study of three healthy men, it did tan them — and it also produced nausea, drowsiness, and spontaneous erections lasting one to five hours.^[3] That second finding is the hinge of the whole melanotan story. In the telling that later appeared in a review co-written by the peptide's own inventors, one of the researchers — named only as a self-described "human pincushion" — is said to have accidentally injected a double dose and developed an eight-hour erection along with nausea.^[4] The anecdote is retold rather than documented, and the source never names the person, so treat the dramatic version with care; what is beyond doubt is the effect itself, which the formal volunteers and a later placebo-controlled trial both recorded.^[3][5] Chemists chased that side effect, reworked the scaffold to keep the arousal and drop most of the pigment, and turned it into bremelanotide. The tanning peptide, in other words, spun off an approved sex-drive drug — the clearest sign of how little the body separates these signals.

Why it tans you

The tanning is straightforward melanocortin biology. MT-II activates MC1R on your melanocytes, which raises cyclic AMP and pushes pigment production toward brown-black eumelanin — the same switch the sun's UV would normally flip, but triggered chemically and without sunlight.^[8] Eumelanin is the photoprotective pigment, the kind that shields DNA rather than the reddish pheomelanin that doesn't, which is why the effect is real enough to appeal to people who burn rather than tan.^[9] It builds pigment in skin that otherwise won't make much. On the site's binding matrix, MT-II grips MC1R about as tightly as any melanocortin measured — a superpotent key for the pigment lock.

Why it also does much more than tan

Here is the catch the marketing skips: MT-II is non-selective, so it doesn't only hit the pigment receptor. One dose reaches all four receptors at once. Activating MC4R in the brain is why users report nausea (commonly half of them or more), facial flushing, loss of appetite, drowsiness, yawning, and spontaneous erections — the last so reliable it became the entire basis of bremelanotide.^[3] The tan people want and the effects they don't are not separable options; they are the same molecule reaching receptors that sit all over the body and brain.

It is worth correcting a common shorthand here, because it bears on the risks. Melanotan-I is often called the "MC1R-selective" one and MT-II the "non-selective" one. That is not quite true: both are broad, superpotent agonists, and recent structural work describes Melanotan-I's parent NDP-α-MSH plainly as "a non-selective" melanocortin agonist.^[7] Genuine receptor selectivity had to be engineered later — a single swap at position 7 turns MT-II into SHU9119, an MC4R-blocking research tool.^[6] The real difference between the two melanotans is practical, not a clean selectivity switch: afamelanotide is delivered as a slow-release implant at controlled exposure for a medical reason, while MT-II is self-injected in boluses — and its breadth is exactly why the effects below come bundled with the tan. For the full mechanism of why these agonists make you queasy and darken, see the trade-off; because MT-II and PT-141 are so often confused, there is also a side-by-side PT-141 vs Melanotan breakdown.

What the human studies actually showed

The biology is genuinely established, and it is worth being precise about how. In a controlled trial published in JAMA, subcutaneous Melanotan-I reliably tanned volunteers — the landmark demonstration that a melanocortin peptide induces pigment in people.^[10] A later study in 65 fair-skinned volunteers went further: Melanotan-I not only raised melanin density but cut UV-induced sunburn cells by more than half and DNA thymine-dimer formation by around 59% — evidence the pigment it builds is meaningfully photoprotective.^[11] Melanotan II itself was shown to tan humans in its small phase-I study.^[3] Two honest caveats follow from this. First, these were small, short pilot studies of the medical analogues, not safety data for years of grey-market MT-II. Second, "some photoprotection in a trial" is not "you can skip sunscreen" — no melanotan has been shown to prevent skin cancer, and the only melanocortin that builds protective pigment as an approved medicine, afamelanotide, exists for a rare disease, not cosmetic tanning.

The risks that matter

Beyond the everyday side effects, a handful of specific concerns are why dermatologists and regulators single this compound out. The honest framing is important: most of the serious harms below come from individual case reports, which show a temporal association, not proof of cause — and melanotan users often also use sunbeds, a confounder that has to be named. The two things thatare well established are that the product is chemically impure and that it drives pigment cells hard.

Moles and melanoma

This is the concern with the strongest mechanistic logic. MT-II darkens existing moles and is associated with the rapid appearance of new ones — "eruptive nevi" — which is exactly what you would predict from a drug that pushes melanocytes.^[12][13] Dermatologists' deeper worry is that driving already-abnormal moles this hard could nudge them toward melanoma, and there are published case reports of melanoma, including melanoma in situ, emerging during or shortly after use.^[14][15] Causation isn't proven and the heavy-UV confounder is real — but the reports exist, the mechanism is plausible, and a chemical tan can mask exactly the mole changes you are meant to watch for. That masking, on its own, is a reason for caution.

Serious, if uncommon, systemic events

A scatter of single case reports documents rarer but severe events after MT-II injection: sympathomimetic toxicity with rhabdomyolysis (muscle breakdown) and kidney impairment;^[16] posterior reversible encephalopathy syndrome, a brain disturbance seen on imaging;^[17] renal (kidney) infarction;^[18] and priapism, a painful, prolonged erection needing emergency treatment — the arousal effect turned dangerous.^[19] Each is a single report from uncontrolled use, where dose and product quality are unknown variables, so none should be read as a common outcome. Taken together, though, they map the ways a superpotent, broadly-acting peptide can go wrong when it is dosed by guesswork.

An unregulated product

Because it is sold illegally, no one verifies what is in the vial. That is not a hypothetical: when researchers bought MT-II "skin-tanning products" from online shops and analysed them, the actual peptide content ran well under the labelled dose — around 4.3 to 8.8 mg where 10 mg was claimed — with measurable impurities in every sample.^[20] Australia's medicines regulator found the same in 2026, testing a "triple strength" nasal spray labelled 30 mg and measuring 22 to 54 mg.^[26] On top of impurity and mis-dosing, self-injection and needle-sharing carry their own infection risks, documented as melanotan spread through injecting and bodybuilding communities.^[21][23] Users themselves describe reaching for it to tan before holidays or fitness competitions, and report the mole changes, nausea and libido effects first-hand.^[24]

It is not approved, and not legal to sell

Melanotan II has never completed the safety trials a medicine requires, and it is unlicensed in the US, UK, EU, and Australia. The US FDA has treated it as an unapproved new drug and warned sellers;^[25] Australia's TGA warns against tanning products containing melanotan and has flagged their inconsistent dosing;^[26] and the UK's MHRA stated years ago that the "tan jab" is an unlicensed medicine that may not be safe.^[27] Dermatology reviews reach the same conclusion from the clinical side: the risks of unregulated α-MSH analogues outweigh a cosmetic tan, and they should not be confused with the tested, approved analogue.^[21][22] The "research chemical" label on what is plainly marketed for human use is a way around approval, not evidence of safety.

The honest bottom line

The biology is real, and genuinely elegant: melanotan does build a sunless tan, through exactly the MC1R pathway this site is built around — the system's oldest trick, pigment on demand.^[8] But the popular version, MT-II, is unapproved, illegal to sell, of unknown quality, and carries real documented risks — including to the very moles a tan can hide. The only approved melanocortin that builds protective pigment, afamelanotide, exists for a rare medical condition under close supervision, not for cosmetic tanning. There is, at present, no approved melanocortin tanning product. We document the science so the decision is an informed one — and so that the wonder of the mechanism is never mistaken for a clean bill of health for the vial.

Common questions

Is melanotan legal?+

Melanotan II is not an approved medicine in the US, UK, EU, or Australia, and selling or advertising it is illegal in those markets. It is labelled a "research chemical, not for human use" to sidestep approval, and regulators including the US FDA, the UK’s MHRA, and Australia’s TGA have all warned against it and acted against sellers.

Does melanotan cause melanoma or skin cancer?+

It has not been proven to, but there is real reason for concern. Melanotan II drives pigment cells hard; it darkens existing moles and is linked in case reports to crops of new ones and to melanoma appearing during or shortly after use. Those are individual reports, not proof of cause — and users tend also to use sunbeds, a confounder — but the mechanism is plausible, and a chemical tan can mask the very mole changes that signal skin cancer.

What is the difference between Melanotan I and Melanotan II?+

Both are lab-made, superpotent relatives of the natural hormone α-MSH, and both are broad melanocortin agonists — neither is truly receptor-selective. Melanotan-I is the linear version developed for pigment; it became the approved, controlled-release drug afamelanotide (Scenesse). Melanotan II is a more potent cyclic redesign that was pushed as a tanning agent, never approved, and is the one sold on the grey market.

Is melanotan the same as afamelanotide?+

They are related but not the same. Afamelanotide is the approved, controlled-release Melanotan-I medicine used for a rare light-sensitivity disorder, given as an implant under medical supervision. Melanotan II is the unapproved grey-market tanning peptide, self-injected at unknown doses.

Why does melanotan make you feel sick?+

Because it is non-selective, Melanotan II also activates MC4R in the brain, which causes nausea, flushing, drowsiness and loss of appetite alongside the tanning — the same melanocortin pharmacology behind the approved drugs’ side effects. Nausea was reported by the very first human volunteers who received it.

Does a melanotan tan protect me from the sun, so I can skip sunscreen?+

No — do not treat it as protection. The tan is real eumelanin, and in trials the medical analogue did modestly reduce UV damage markers, but a melanotan tan has never been shown to prevent sunburn reliably or lower skin-cancer risk, and the grey-market product is unapproved and impure. Worse, a false sense of protection plus a tan that hides mole changes is the exact combination dermatologists worry about. Normal sun protection still applies. This is education, not medical advice.

Is the melanotan nasal spray safer than injecting it?+

It is not a safe alternative. The spray delivers the same unapproved peptide, is still absorbed into the bloodstream, and produces the same MC4R effects — and the dose is even harder to control. In 2026 Australia’s TGA tested a "triple strength" nasal spray labelled 30 mg and found the actual content ranged from 22 to 54 mg. Different route, same drug and the same unknowns.

References

1. 1.Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 32(12):2555–61. 1989. link ↗
2. 2.Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 27(4):921–30. 2006. link ↗
3. 3.Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 58(20):1777–84. 1996. link ↗
4. 4.King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 7(11):1098–1106. 2007. link ↗
5. 5.Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 160(2):389–93. 1998. link ↗
6. 6.Schiöth HB, Muceniece R, Mutulis F, et al. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides. 18(7):1009–13. 1997. link ↗
7. 7.Heyder NA, Kleinau G, Speck D, et al. Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide. Cell Res. 31(11):1176–1189. 2021. link ↗
8. 8.Swope VB, Abdel-Malek ZA. MC1R: front and center in the bright side of dark eumelanin and DNA repair. Int J Mol Sci. 19(9):2667. 2018. link ↗
9. 9.Nasti TH, Timares L. MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer. Photochem Photobiol. 91(1):188–200. 2015. link ↗
10. 10.Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 266(19):2730–6. 1991. link ↗
11. 11.Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-α-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 126(8):1869–78. 2006. link ↗
12. 12.Cardones AR, Grichnik JM. α-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 145(4):441–4. 2009. link ↗
13. 13.Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed "sun tan jab". BMJ. 338:b277. 2009. link ↗
14. 14.Paurobally D, Jason F, Dezfoulian B, Nikkels AF. Melanotan-associated melanoma. Br J Dermatol. 164(6):1403–5. 2011. link ↗
15. 15.Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 228(1):34–6. 2014. link ↗
16. 16.Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 50(10):1169–73. 2012. link ↗
17. 17.Kaski D, Stafford N, Mehta A, Jenkins IH, Malhotra P. Melanotan and the posterior reversible encephalopathy syndrome. Ann Intern Med. 158(9):707–8. 2013. link ↗
18. 18.Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction — review of the literature and case report. CEN Case Rep. 9(2):159–61. 2020. link ↗
19. 19.Mallory CW, Lopategui DM, Cordon BH. Melanotan tanning injection: a rare cause of priapism. Sex Med. 9(1):100298. 2021. link ↗
20. 20.Breindahl T, Evans-Brown M, Hindersson P, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 7(2):164–72. 2015. link ↗
21. 21.Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol. 163(3):451–5. 2010. link ↗
22. 22.Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 56(10):975–80. 2017. link ↗
23. 23.Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 338:b566. 2009. link ↗
24. 24.Gilhooley E, Daly N, McKenna D. Melanotan II user experience: a qualitative study of online discussion forums. Dermatology. 237(6):995–9. 2021. link ↗
25. 25.US Food & Drug Administration. Warning letter: melanopharmacy.com (ref. 610314) — Melanotan II marketed as an unapproved new drug. Regulatory action. 2020. link ↗
26. 26.Therapeutic Goods Administration (Australia). Melanotan II tanning peptide products found to be inconsistently dosed. Safety alert. 2026. link ↗
27. 27.Medicines and Healthcare products Regulatory Agency (UK). 'Tan jab' is an unlicensed medicine and may not be safe. Media statement (archived, The National Archives). 2008. link ↗